Abstract 9P
Background
To evaluate clinicopathological features and prognosis in women with mucinous breast cancer (MBC), distinguishing between pure (PMC) and mixed (MMC) subtype.
Methods
A retrospective analysis of all 358 women with MBC treated at Vietnam National Cancer hospital from June 2015 to December 2020. PMC was defined by ≥ 90% mucinous components.
Results
We identified 358 women with MBC (245 PMC and 113 MMC) representing 2.7% of all 13,254 breast cancer patients. The proportion of stage I, II, III and IV were 34.9%, 50.8%, 10.4% and 3.9% respectively. 95.3% of patients were hormone receptor positive. The rate of HER2 overexpression is 12%, and only 1.4% of patients was treated with anti-HER2. 193 patients (53.9%) had chemotherapy (CT), including 55 patients (15.4%) treated in neoadjuvant setting. Among those received neoadjuvant CT, only 3 patients (5.5%) achieved pCR. Meanwhile, the rates of partial response, stable disease and progressive disease were 50.8%, 38.2% and 5.5% respectively. PMC patients were older (54.4±13.3 vs 51.1±13.1 years), had lower Ki67 expression, lower incidence of nodal metastasis (N+) than MMC patients (p values <0.05). At median follow-up of 58 months, the 5-year overall survival rate of non-metastatic patients was 86.6%. Univariate analysis revealed that significant factors for poorer OS were MMC subtype (p=0.02), large tumor size (T) (p<0.001), N+ (p<0.001), HER2 overexpression (p<0.001), PR negative (p=0.02), and high Ki67 (p=0.02). Multivariate analysis showed nodal metastasis (N+) to be the most significant prognostic factor (HR=3.3; 95%CI 1.5-7.1), followed by high T stage (HR=2.9; 95%CI 1.4-6.3), HER2 overexpression (HR=2.5; 95%CI 1.2-5.3) and MMC subtype (HR=1.9; 95%CI 1.0-3.9). Amongst 245 patients with stage T1-2N0M0, 40.8% of those treated with CT related to worse overall survival (5-year OS 88.0% vs 95.6%, p=0.04).
Conclusions
The majority of MBC are luminal subtypes and associated with good prognosis. Poor prognostic factors of women with MBC are high T, N stage, HER2 overexpression and MMC subtype. Chemotherapy in stage T1-2N0M0 brings a worse survival outcome compared to endocrine therapy. Given the low response rate to neoadjuvant CT, upfront surgery is appropriate for MBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract